Buchumschlag

Robust and cost‐effective CRISPR/Cas9 gene editing of primary tumor B cells in Eµ‐TCL1 model of chronic lymphocytic leukemia

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Rosita Del Prete, Roberta Drago, Federica Nardi, Gaia Bartolini, Erika Bellini, Antonella De Rosa, Silvia Valensin, Anna Kabanova
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	HemaSphere
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

IL21—STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemia
von: Rosita Del Prete, et al.
Veröffentlicht: (2026)

NK‐type large granular lymphocyte leukemia comes of age
von: Gianpietro Semenzato, et al.
Veröffentlicht: (2025)

Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
von: Kostas Stamatopoulos, et al.
Veröffentlicht: (2024)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
von: Raúl Córdoba, et al.
Veröffentlicht: (2026)

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
von: Thomas Chatzikonstantinou, et al.
Veröffentlicht: (2024)

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience
von: Idanna Innocenti, et al.
Veröffentlicht: (2024)

Extracellular vesicles from chronic lymphocytic leukemia cells promote leukemia aggressiveness by inducing the differentiation of monocytes into nurse‐like cells via an RNA‐dependent mechanism
von: Nathan Dubois, et al.
Veröffentlicht: (2025)

Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
von: Arnon P. Kater, et al.
Veröffentlicht: (2024)

Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020
von: Lina van der Straten, et al.
Veröffentlicht: (2024)

Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience
von: Paolo Ghia, et al.
Veröffentlicht: (2025)

Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B‐cell‐related epigenetic imprinting and genetic alterations
von: Stella Charalampopoulou, et al.
Veröffentlicht: (2026)

CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience
von: Riccardo Bomben, et al.
Veröffentlicht: (2024)

Comparative analysis of macrophage feeder systems reveals distinct behaviors and key transcriptional shifts in chronic lymphocytic leukemia cells via coculture
von: Viktoria Kohlhas, et al.
Veröffentlicht: (2025)

A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia
von: Elisa Lenti, et al.
Veröffentlicht: (2025)

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
von: Gian Matteo Rigolin, et al.
Veröffentlicht: (2024)

3D Tumor microenvironment interaction reveals AP‐1 complex regulation and contact‐mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia
von: Jana Lindacher, et al.
Veröffentlicht: (2025)

Unveiling relative lymphopenia and elevated monocyte‐to‐lymphocyte count as novel independent adverse prognostic factors in chronic myelomonocytic leukemia (CMML)—Proposal of the objective prognostic index for CMML (OPIC)
von: Xavier Calvo, et al.
Veröffentlicht: (2026)

First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis
von: Paolo Ghia, et al.
Veröffentlicht: (2024)

Chronic lymphocytic leukemia with IGH :: BCL3 ‐translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape
von: Cosima Drewes, et al.
Veröffentlicht: (2026)

De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria
von: Peter Johnstone, et al.
Veröffentlicht: (2025)

HLA diversity is associated with TKI response and treatment‐free remission in chronic myeloid leukemia
von: Charles Toulemonde, et al.
Veröffentlicht: (2025)

Circulating tumor‐associated and neoantigen‐specific endogenous T cells in children treated for B‐acute lymphoblastic leukemia
von: Eliane Huwiler, et al.
Veröffentlicht: (2025)

An integrated classification of tumor suppressor IKZF1 inactivation and oncogenic activation in Philadelphia chromosome‐like acute lymphoblastic leukemia
von: Zicong Huang, et al.
Veröffentlicht: (2024)

Diagnosis without consent: A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
von: Richard J. Buka
Veröffentlicht: (2026)

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second‐line therapy in pediatric chronic myeloid leukemia
von: Stephanie Sembill, et al.
Veröffentlicht: (2026)

Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
von: Daniel Mazza Matos
Veröffentlicht: (2026)

Dynamic evolution of TCF3‐PBX1 leukemias at the single‐cell level under chemotherapy pressure
von: Mira Kusterer, et al.
Veröffentlicht: (2025)

Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study
von: André Baruchel, et al.
Veröffentlicht: (2025)

Inflammatory signaling in the pathogenesis of acute myeloid leukemia
von: Artemis Margrith Baumann, et al.
Veröffentlicht: (2025)

Impact of the kinetics of circulating anti‐BCMA CAR‐T cells and normal lymphocytes on the outcome of MM patients
von: Sara Gutiérrez‐Herrero, et al.
Veröffentlicht: (2025)

Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T‐cell lymphoblastic leukemia
von: André Almeida, et al.
Veröffentlicht: (2024)

Hyperdiploid acute lymphoblastic leukemia in children with LZTR1 germline variants
von: Lisa Zipper, et al.
Veröffentlicht: (2024)

Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
von: Rebeqa Gunnarsson, et al.
Veröffentlicht: (2025)

Chronic graft‐versus‐host disease in long‐term survivors of childhood leukemia
von: Paul Saultier, et al.
Veröffentlicht: (2026)

Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in acute myeloid leukemia
von: Francesco Leonetti, et al.
Veröffentlicht: (2025)

HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
von: Sophie Le Grand, et al.
Veröffentlicht: (2025)

Cell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia
von: Hansen J. Kosasih, et al.
Veröffentlicht: (2025)

Correction to “Influence of donor–recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation”
Veröffentlicht: (2024)

Neuroinflammatory changes in acute myeloid leukemia: Evidence for blood–brain barrier disruption and glial activation
von: Marta Febo, et al.
Veröffentlicht: (2026)

Ponalfil trial for adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia: Long‐term results
von: Josep‐Maria Ribera, et al.
Veröffentlicht: (2024)